US Multicenter Experience With the Wingspan Stent System for the Treatment of Intracranial Atheromatous Disease
Authors:
- David FiorellaDFDavid Fiorella
- Elad I. LevyELElad I. Levy
- Aquilla S. TurkATAquilla S. Turk
- Felipe C. AlbuquerqueFAFelipe C. Albuquerque
- David B. NiemannDNDavid B. Niemann
- Beverly Aagaard-KienitzBABeverly Aagaard-Kienitz
- Ricardo A. HanelRHRicardo A. Hanel
- Henry WooHWHenry Woo
- Peter A. RasmussenPRPeter A. Rasmussen
- L. Nelson HopkinsLHL. Nelson Hopkins
- Thomas J. MasarykTMThomas J. Masaryk
- Cameron G. McDougallCMCameron G. McDougall
- 1 March 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (3) , 881-887
Abstract
Background and Purpose— The current report details our initial periprocedural experience with Wingspan (Boston Scientific/Target), the first self-expanding stent system designed for the treatment of intracranial atheromatous disease. Methods— All patients undergoing angioplasty and stenting with the Gateway balloon–Wingspan stent system were prospectively tracked. Results— During a 9-month period, treatment with the stent system was attempted in 78 patients (average age, 63.6 years; 33 women) with 82 intracranial atheromatous lesions, of which 54 were ≥70% stenotic. Eighty-one of 82 lesions were successfully stented (98.8%) during the first treatment session. In 1 case, the stent could not be delivered across the lesion; the patient was treated solely with angioplasty and stented at a later date. Lesions treated involved the internal carotid (n=32; 8 petrous, 10 cavernous, 11 supraclinoid segment, 3 terminus), vertebral (n=14; V4 segment), basilar (n=14), and middle cerebral (n=22) arteries. Mean±SD pretreatment stenosis was 74.6±13.9%, improving to 43.5±18.1% after balloon angioplasty and to 27.2±16.7% after stent placement. Of the 82 lesions treated, there were 5 (6.1%) major periprocedural neurological complications, 4 of which ultimately led to patient death within 30 days of the procedure. Conclusions— Angioplasty and stenting for symptomatic intracranial atheromatous disease can be performed with the Gateway balloon–Wingspan stent system with a high rate of technical success and acceptable periprocedural morbidity. Our initial experience indicates that this procedure represents a viable treatment option for this patient population.Keywords
This publication has 10 references indexed in Scilit:
- Angioplasty for Symptomatic Intracranial StenosisStroke, 2006
- Predictors of Ischemic Stroke in the Territory of a Symptomatic Intracranial Arterial StenosisCirculation, 2006
- Stent-angioplasty of intracranial vertebral and basilar artery stenoses in symptomatic patientsEuropean Journal of Radiology, 2005
- Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial StenosisNew England Journal of Medicine, 2005
- Long-term outcome of endovascular stenting for symptomatic basilar artery stenosisNeurology, 2005
- Elective stenting for symptomatic middle cerebral artery stenosis presenting as transient ischaemic deficits or stroke attacks: short term arteriographical and clinical outcomeJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Stenting of Symptomatic M1 Stenosis of Middle Cerebral ArteryStroke, 2004
- Angioplasty for Intracranial Symptomatic Vertebrobasilar IschemiaNeurosurgery, 2002
- Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term resultsJournal of Neurosurgery, 1999
- Failure of Extracranial–Intracranial Arterial Bypass to Reduce the Risk of Ischemic StrokeNew England Journal of Medicine, 1985